RCE/1644/B II

PTO/SB/30 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

REQUEST FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL

Subsection (b) of 35 U.S.C. 132, effective on May 29, 2000, provides for continued examination of an utility or plant application filed on or after June 8, 1995.
See The American Inventors Protection Act of 1999 (AIPA).

Application Number	09/615,437
Filing Date	July 13, 2000
First Named Inventor	Christopher M. Kim
Group Art Unit	1644
Examiner Name	HUYNH, P.
Attorney Docket No.	CKIM 3.0-001

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application.

NOTE: 37 CFR 1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000, applicant may wish to consider filing a continued prosecution application (CPA) under 37 CFR 1.53(d) (PTO/SB/29) instead of a RCE to be eligible for the patent term adjustment provisions of the AIPA. See *Changes to Application Examination and Provisional Application Practice,* Final Rule, 65 *Fed. Reg. 50092* (Aug. 16, 2000); Interim Rule, 65 *Fed. Reg.* 14865 (Mar. 20, 2000), *1233 Off. Gaz. Pat Office* 47 (Apr. 11, 2000) which established RCE practice.

1. Submission required under 37 CFR 1.114
   - a. [ ] Previously submitted
     - i. [ ] Consider the amendment(s)/reply under 37 CFR 1.116 previously filed on _____ (Any unentered amendment(s) referred to above will be entered).
     - ii. [ ] Consider the arguments in the Appeal Brief or Reply Brief previously filed on _____
     - iii. [ ] Other _____
   - b. [x] Enclosed
     - i. [x] Amendment/Reply
     - ii. [ ] Affidavit(s)/Declaration(s)
     - iii. [ ] Information Disclosure Statement (IDS)
     - iv. [ ] Other _____

2. Miscellaneous
   - a. [ ] Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of _____ months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) **required**)
   - b. [ ] Other _____

3. Fees — The RCE fee under 37 CFR 1.17 (e) is required by 37 CFR 1.114 when the RCE is filed.
   - a. [x] The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 12-1095
     - i. [x] RCE fee required under 37 CFR 1.17(e) 10/17/2001 AWONDAF1 00000065 121095 09615437
     - ii. [ ] Extension of time fee (37 CFR 1.136 and 1.17) 01 FC:279 370.00 CH
     - iii. [ ] Other _____
   - b. [ ] Check in the amount of $ _____ Enclosed
   - c. [ ] Payment by credit card (Form PTO-2038 enclosed)

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

Name (Print/Type)	Lance Y. Liu	*Registration No. (Attorney/Agent)*	45,379
Signature	lance liu	*Date*	October 11, 2001

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: October 11, 2001 Signature: lance liu (Lance Y. Liu)

12/C
ES/10/19/01

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Box AF, Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: October 11, 2001 Signature: lance liu (Lance Y. Liu)

EXPEDITED PROCEDURE
EXAMINING GROUP 1644
Docket No.: CKIM 3.0-001
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Christopher M. Kim

Application No.: 09/615,437 Group Art Unit: 1644

Filed: July 13, 2000 Examiner: HUYNH, P.

For: BEE VENOM TREATMENT WITHOUT THE STING

AMENDMENT UNDER 37 CFR 1.116

Box AF
Commissioner for Patents
Washington, DC 20231

Dear Sir:

In response to the Advisory Action mailed August 29, 2001, applicant submits the following amendments and remarks.

IN THE CLAIMS

CLEAN COPY OF AMENDED CLAIMS:

Please cancel claims 12-14, 19, 23 and 24.

11. (Amended) A method of administering bee venom to a patient in need of such treatment comprising the steps of:

administering to a patient, simultaneously or consecutively, (1) between about 0.01 mg and about 1.0 mg per injection of bee venom intradermally, subcutaneously or intramuscularly and (2) at least one anesthetic in an amount of 0.3mg or less per injection, intradermally, subcutaneously or intramuscularly, wherein the administration of said anesthetic reduces the irritation associated with the injection of said bee venom.

C1